Form 4: Eledon Pharmaceuticals President Acquires 428,148 Shares Through Stock Option Vesting

Steven Perrin, President of Eledon Pharmaceuticals, acquired 428,148 shares of common stock through the vesting of a stock option on June 13, 2024.

Summary

• Steven Perrin, President of Eledon Pharmaceuticals, acquired 428,148 shares of common stock through the vesting of a stock option.
• The transaction occurred on June 13, 2024, and is related to an option award granted on May 1, 2023.
• The option's performance-based vesting criteria were met for 428,148 shares on June 13, 2024.
• Time-based vesting criteria were met for 107,037 shares on May 1, 2024.
• The remaining 321,111 shares will vest in substantially equal quarterly installments over three years, ending May 1, 2027.
• The exercise price of the stock option is $2.30.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing an executive's stock option vesting. It's neutral in tone, but the vesting itself suggests the company is meeting performance goals, which is mildly positive.

Positives

• The vesting of performance-based stock options suggests that the company is achieving its goals, which could be seen as a positive sign.

Future Outlook

The remaining 321,111 shares will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Industry Context

Form 4 filings are routine disclosures of insider transactions and are common in the pharmaceutical industry.

Stakeholder Impact

• The vesting of stock options can have a minor dilutive effect on existing shareholders.

Next Steps

• The remaining 321,111 shares will vest quarterly until May 1, 2027.

Key Dates